Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2017

View Archived Issues

Codexis enters protein engineering platform collaboration with Nestle Health Science

IDRI announces first-in-human study of leprosy vaccine candidate LepVax

Flex Pharma begins phase II study of FLX-787

Cognition Therapeutics' CT-1812 awarded FDA fast track designation

CELESTIAL study of cabozantinib meets primary endpoint, FDA grants priority review for untreated RCC

First study in infants conducted for MEDI-8897, phase II study underway

Philogen cleared by FDA to conduct phase III Daromun registration trial

NIAID presents phase II data for two Ebola vaccines

Inovio Pharmaceuticals commences phase Ib/II combination study in bladder cancer

Aimmune Therapeutics enters clinical collaboration with Sanofi and Regeneron

Dicerna Pharmaceuticals seeks to conduct phase I study of DCR-PHXC in U.K.

FDA clears ImmunoGen's IND for phase I study of IMGN-632

Aeglea BioTherapeutics, Merck & Co. to evaluate AEB-1102 with pembrolizumab in SCLC

Engineered replication-defective cytomegalovirus vaccine V-160 immunogenic in phase I study

Cara Therapeutics planning phase III pivotal program for CR-845

Jiangsu Chia Tai Tianqing Pharmaceutical and collaborators patent mutant IDH1 inhibitors

Cerveau Technologies, Janssen enter [18F]MK-6240 research agreement

Novel SERDs discovered by Medshine Discovery, Shandong Luoxin Pharmacy Group Co.

Johns Hopkins presents novel drug conjugates inhibiting glutamate carboxypeptidase 2

Amgen and Boston Children's Hospital collaborate to identify novel pain targets

FDA grants priority review to Imfinzi sBLA for locally advanced unresectable NSCLC

Mouse model of Phelan-McDermid syndrome developed

Halozyme begins study of PEGPH20 with atezolizumab

Abeona Therapeutics receives grants from Sanfilippo syndrome foundations

IGeneX launches three new tests for Lyme disease and tick-borne relapsing fever

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...